Valsartan scandal draws in a further two companies

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Oakozhan)
(Image: Getty/Oakozhan)

Related tags valsartan Fda Ema

The global investigation into the valsartan scandal continues to broaden, as two additional companies are drawn under the lens of the FDA and EMA.

The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have named Torrent Pharmaceuticals and Zhejiang Tianyu, respectively, as part of wider action to limit the spread of contaminated valsartan.

For Torrent Pharmaceuticals, the FDA announced it had issued a voluntary recall for 14 lots of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide tablets. The active pharmaceutical ingredient (API) used in its products was supplied by Zhejiang Huahai.

Zhejiang Huahai was at the centre of the global recall of valsartan products last month​, after EMA inspectors discovered that the company’s API contained an impurity known as N-nitrosodimethylamine (NDMA). This particular chemical has been listed as a probable carcinogenic.

Earlier this month, it came to light that Zhejiang Huagai had received two Form 483s​ from the US regulator, in 2016 and 2017

The FDA announced that Torrent had not received any reports of adverse events related to the recall, but was instead a precautionary measure.

At the time of publishing, Torrent Pharmaceuticals had not responded to a request for comment.

Another Chinese company involved

Widening the possible sources of the contaminated API is the EMA’s announcement that Zhejiang Tianyu is no longer authorised to manufacture the same ingredient. This decision was reached after the EMA concluded​ that the company had also produced the valsartan active substance with NDMA contamination.

However, the Agency noted that levels of NDMA were “considerably lower than levels found in the active substance from Zhejiang Huahai”. ​Despite this, the Agency was concerned enough to suspend the company’s certificate by the European Directorate for the Quality of Medicines and Healthcare.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more